Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates

Deanna J. Buehrle; Ryan K. Shields; Liang Chen; Binghua Hao; Ellen G. Press; Ammar Alkrouk; Brian A. Potoski; Barry N. Kreiswirth; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1128/AAC.02969-15

Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates

Deanna J. Buehrle
, Ryan K. Shields
, Liang Chen
, Binghua Hao
, Ellen G. Press
, Ammar Alkrouk
, Brian A. Potoski
, Barry N. Kreiswirth
, Cornelius J. Clancy
, M. Hong Nguyen

Center for Discovery and Innovation

University of Pittsburgh
Rutgers - The State University of New Jersey, Newark
VA Medical Center

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Abstract

We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime- avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.

Original language	English
Pages (from-to)	3227-3231
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	60
Issue number	5
DOIs	https://doi.org/10.1128/AAC.02969-15
State	Published - May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.02969-15

Cite this

Buehrle, D. J., Shields, R. K., Chen, L., Hao, B., Press, E. G., Alkrouk, A., Potoski, B. A., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016). Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrobial Agents and Chemotherapy, 60(5), 3227-3231. https://doi.org/10.1128/AAC.02969-15

@article{152dabdb0bad455daffcac67fff7da64,

title = "Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates",

abstract = "We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74\% were oprD mutants. Ceftazidime- avibactam and ceftolozane-tazobactam were active against 92\% of the isolates, including 80\% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6\% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.",

author = "Buehrle, \{Deanna J.\} and Shields, \{Ryan K.\} and Liang Chen and Binghua Hao and Press, \{Ellen G.\} and Ammar Alkrouk and Potoski, \{Brian A.\} and Kreiswirth, \{Barry N.\} and Clancy, \{Cornelius J.\} and Nguyen, \{M. Hong\}",

year = "2016",

month = may,

doi = "10.1128/AAC.02969-15",

language = "English",

volume = "60",

pages = "3227--3231",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

Buehrle, DJ, Shields, RK, Chen, L, Hao, B, Press, EG, Alkrouk, A, Potoski, BA, Kreiswirth, BN, Clancy, CJ & Nguyen, MH 2016, 'Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates', Antimicrobial Agents and Chemotherapy, vol. 60, no. 5, pp. 3227-3231. https://doi.org/10.1128/AAC.02969-15

TY - JOUR

T1 - Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates

AU - Buehrle, Deanna J.

AU - Shields, Ryan K.

AU - Chen, Liang

AU - Hao, Binghua

AU - Press, Ellen G.

AU - Alkrouk, Ammar

AU - Potoski, Brian A.

AU - Kreiswirth, Barry N.

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

PY - 2016/5

Y1 - 2016/5

N2 - We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime- avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.

AB - We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime- avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.

UR - https://www.scopus.com/pages/publications/84964939441

U2 - 10.1128/AAC.02969-15

DO - 10.1128/AAC.02969-15

M3 - Article

C2 - 26976862

AN - SCOPUS:84964939441

SN - 0066-4804

VL - 60

SP - 3227

EP - 3231

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

ER -

Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this